Novartis Activates Conatus NASH Med Deal

May 04, 2017

Reuters

Novartis is exercising its option with California-based Conatus Pharmaceuticals for an exclusive license for the global development and commercialization of emricasan for treating liver disease NASH.

In December, Novartis signed a $50 million up front licensing deal to co-develop the fatty liver disease drug with Conatus. Emricasan, in midstage testing, is a first-in-class, pan-caspase inhibitor for the treatment of nonalcoholic steatohepatitis (NASH) with advanced scarring and cirrhosis.

Conatus is small biotech company focused on the development and commercialization of novel medicines to treat liver disease.

Read the Reuters coverage

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments